8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
Published . Updated .
Key takeaways
- 8-K - Perspective Therapeutics filed an 8-K with the SEC on Nov 6 (a notice of a material company event).
- Exposed: CATX
- Market reaction: CATX +5.9% on the day (still updating)
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - Perspective Therapeutics filed an 8-K with the SEC on Nov 6 (a notice of a material company event).
Directly affected
- CATX Perspective Therapeutics-67.7% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Perspective Therapeutics belongs to, so it often moves with news about it.
- LLY Eli Lilly and+19.9% 30d
Eli Lilly and is a peer of Perspective Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson+1.9% 30d
Johnson & Johnson is a peer of Perspective Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie+11.3% 30d
AbbVie is a peer of Perspective Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck+5.9% 19d
Merck is a peer of Perspective Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories+12.7% 30d
Abbott Laboratories is a peer of Perspective Therapeutics in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| CATX | +43.73% | +11.66% | base | +5.91% | after close | after close | after close |
| XLV | -0.05% | -0.52% | base | -0.28% | after close | after close | after close |
| LLY | +3.64% | +3.08% | base | -0.08% | after close | after close | after close |
| JNJ | +0.29% | -2.31% | base | +0.32% | after close | after close | after close |
| ABBV | +2.38% | -0.72% | base | +0.32% | after close | after close | after close |
| MRK | +1.80% | -1.52% | base | -0.13% | after close | after close | after close |
| ABT | -6.44% | -3.65% | base | -2.46% | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-06 AccNo: 0001193125-26-451227 Size: 1 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
The price since 6 Nov 2026: Perspective Therapeutics (CATX) versus the S&P 500
| Company | When | Move | Status |
|---|---|---|---|
| ABBV | that day | +0.32% | still updating |
| ABBV | three days earlier | -0.72% | final price |
| ABBV | five days earlier | +2.38% | final price |
| ABT | that day | -2.46% | still updating |
| ABT | three days earlier | -3.65% | final price |
| ABT | five days earlier | -6.44% | final price |
| Perspective Therapeutics (CATX) | that day | +5.91% | still updating |
| Perspective Therapeutics (CATX) | three days earlier | +11.66% | final price |
| Perspective Therapeutics (CATX) | five days earlier | +43.73% | final price |
| JNJ | that day | +0.32% | still updating |
| JNJ | three days earlier | -2.31% | final price |
| JNJ | five days earlier | +0.29% | final price |
| LLY | that day | -0.08% | still updating |
| LLY | three days earlier | +3.08% | final price |
| LLY | five days earlier | +3.64% | final price |
| MRK | that day | -0.13% | still updating |
| MRK | three days earlier | -1.52% | final price |
| MRK | five days earlier | +1.80% | final price |
| XLV | that day | -0.28% | still updating |
| XLV | three days earlier | -0.52% | final price |
| XLV | five days earlier | -0.05% | final price |
Congressional trades in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 63 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 37 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 42 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 59 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 53 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 63 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 43 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 79 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Pete Sessions sold Abbott Laboratories (ABT) (held by a spouse), worth $50,001 - $100,000 on 2 Oct 2026. That is 35 days before publication. Filed 27 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Abbott Laboratories (ABT), worth $1,001 - $15,000 on 18 Sep 2026. That is 49 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Abbott Laboratories (ABT), worth $1,001 - $15,000 on 17 Sep 2026. That is 50 days before publication. Filed 30 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Perspective Therapeutics (CATX)
Companies carried with this story
- CATX Perspective Therapeutics
For “8-K - Perspective Therapeutics, Inc. (0000728387) (Filer),” Perspective Therapeutics (CATX) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> CATX
How “8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)” reaches Perspective Therapeutics (CATX)
Perspective Therapeutics (CATX) is the company in “8-K - Perspective Therapeutics, Inc. (0000728387) (Filer),” the 6 Nov 2026 this story story.
The link for Perspective Therapeutics (CATX) is this: SEC 8-K filing -> direct issuer disclosure -> CATX
Price levels for Perspective Therapeutics (CATX)
CATX traded between 0.84 and 2.75 across 20 sessions. The latest close on file is 0.87.
A simple score for Perspective Therapeutics (CATX)
14 out of 100Price not final
“8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies. The price is not final yet.